Merck to pay Dynavax $4M for Heplisav
(Moreover) Merck & Co. will pay Berkeley's Dynavax Technologies Corp. $4 million to cover costs of the Heplisav program. Whitehouse Station, N.J.-based Merck (NYSE: MRK) dropped a deal to develop the treatment with Dynavax (NASDAQ: DVAX) in December 2008, and t
Empty or Broken Feed 96: (306 failures) Merck and Co news RSS URL: http://p.moreover.com/cgi-local/page?c=Merck%20and%20Co%20news&o=rss002